We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A review of the abuse potential assessment of atomoxetine: a nonstimulant medication for attention-deficit/hyperactivity disorder.
- Authors
Upadhyaya, Himanshu P; Desaiah, Durisala; Schuh, Kory J; Bymaster, Frank P; Kallman, Mary J; Clarke, David O; Durell, Todd M; Trzepacz, Paula T; Calligaro, David O; Nisenbaum, Eric S; Emmerson, Paul J; Schuh, Leslie M; Bickel, Warren K; Allen, Albert J
- Abstract
Treatment of attention-deficit/hyperactivity disorder (ADHD) has for many years relied on psychostimulants, particularly various formulations of amphetamines and methylphenidate. These are central nervous system stimulants and are scheduled because of their abuse potential. Atomoxetine (atomoxetine hydrochloride; Strattera®) was approved in 2002 for treatment of ADHD, and was the first nonstimulant medication approved for this disorder. It was classified as an unscheduled medication indicating a low potential for abuse. However, the abuse potential of atomoxetine has not been reviewed.
- Publication
Psychopharmacology, 2013, Vol 226, Issue 2, p189
- ISSN
1432-2072
- Publication type
Journal Article
- DOI
10.1007/s00213-013-2986-z